Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years.
- Author:
Xing-Li ZHAO
1
;
Shu-Ning WEI
1
;
Kai-Qi LIU
1
;
Dong LIN
1
;
Hui WEI
1
;
Ying WANG
1
;
Chun-Lin ZHOU
1
;
Bing-Cheng LIU
1
;
Wei LI
1
;
Zeng CAO
1
;
Ben-Fa GONG
1
;
Yun-Tao LIU
1
;
Xiao-Yuan GONG
1
;
Yan LI
1
;
Run-Xia GU
1
;
Guang-Ji ZHANG
1
;
Jian-Xiang WANG
1
;
Ying-Chang MI
2
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cytarabine; Dactinomycin; Humans; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Recurrence; Remission Induction; Salvage Therapy
- From: Journal of Experimental Hematology 2015;23(2):396-400
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of MAC regimen in the treatment of acute myeloid leukemia(AML) patients older than 55 years.
METHODSA total of 33 relapsed or non-remission AML patients older than 55 years were enrolled in this research. MAC regimen was given as the salvage treatment. Complete remission rate(CR), partial remission rate(PR), overall survival(OS), relapse-free survival(RFS) and adverse effect were analysed.
RESULTSCR rate after the salvage therapy with MAC was 51.1%, partial remission (PR) rate was 6.1%, the overall response rate (ORR) was 57.6%, the median OS was 8 months (1.0-66.0 months), the median relapse-free survival (RFS) was 10.1 months (2.3-40.4 months). Mortality related with salvage treatment in 30 days was 9.1%. Low incidence of severe organ damage were found.
CONCLUSIONMAC can be used as a relative effective and safe regimen for the salvage treatment of the older AML patients.
